Learn how personalized cancer vaccines work and what to watch for at ESMO 2026. A vaccine made from a person’s own tumor has become the first of its kind to succeed in a phase 3 trial. Full results ...
Learn how mRNA and its lipid packaging change in the bloodstream, offering insights that could help researchers design better ...
A personalised vaccine given in combination with a drug has been shown to stop tumors returning in skin cancer patients. The experimental mRNA cancer drug, called intismeran, which is personalised for ...
Researchers are testing a vaccine approach that may change future cancer treatment.
Trials investigating mRNA vaccines for lung cancer, pancreatic cancer and other diseases are already underway.
Individualized vaccines are built from resected tumor, using analytics to prioritize neoantigens most likely to be immunogenic, then encoding these targets into an mRNA construct tailored to each ...
The personalized mRNA shot teaches the body to attack a patient’s specific melanoma cells A new vaccine could soon protect patients from returning skin cancer. In a large clinical trial, patients with ...
Researchers found that mRNA cancer vaccines can recruit an unexpected immune cell to launch powerful tumor-fighting responses, overturning a long-held assumption about how the vaccines work. The ...
A cancer vaccine may be closer to reality now. Moderna and Merck announced this week that their personalized mRNA melanoma vaccine met key goals in a Phase 3 trial, reducing the risk of the cancer ...
Adults at high risk of melanoma recurrence were able to stay cancer-free in a new vaccine trial. The results bode well for future cancer vaccines. In a late-stage trial, a personalized mRNA cancer ...
In 1948, researchers stressed a nursing mother with ice water, toe pulling, and math problems with shocks. Each time, her baby got less milk. The Old Farmer's Almanac predicts snow in the Upper ...
Researchers are testing cancer vaccines that could help prevent colorectal cancer in people with Lynch syndrome, but the ...